Awards
Recognition reflects employee feedback and comes as UCB expands its Georgia footprint through a $2 billion investment in a new biomanufacturing campus expected to create more than 330 jobs.
From
To
Fda Approval
FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients two years of age and older.¹Post hoc analysis of patients with LGS, transitioning from the randomized controlled trial to an open-label extension study, who started FINTEPLA following placebo and those who continued with FINTEPLA showed rapid improvement in seizure frequency and global functioning.²Rapid clinical improvement in seizure frequency and global functioning were observed in both groups, as mean Fintepla dose was increased.²Safety findings were consistent with known data, with expected increases in common adverse events following FINTEPLA initiation and decreasing incidence over time with continued treatment.²These results showed that sustained FINTEPLA treatment is effective and tolerable.²
Health Care Hospitals
ATLANTA, July 8, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the recipients of its annual UCB Myasthenia Gravis Scholarship,™ awarding 15 scholarships to individuals in the United States who are living with myasthenia gravis (MG) or supporting a loved one impacted by the disease. The scholarship program reflects UCB's continued commitment to supporting the MG community beyond medicine by helping reduce the financial burden associated with pursuing higher education and career development.
Clinical Trials Medical Discoveries
Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.1Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression2 and highlights the benefits of early diagnosis.3
New Products Services
Applications open June 1 for UCB's Hidradenitis Suppurativa Scholarship™ ProgramInformed by patient insights, the initiative builds on UCB's network of scholarship programs in myasthenia gravis and epilepsy
